A server architecture for a digital rights management system that distributes and protects rights in content. The server architecture includes a retail site, a fulfillment site, and an activation site. Each retail site is equipped with a URL encryption object, which encrypts, information that is needed by the fulfillment site to process an order for content sold by the retail site. Upon selling a content item, the retail site transmits to the purchaser a web page having a link to a URL comprising the address of the fulfillment site and a parameter having the encrypted information. Upon following the link, the fulfillment site downloads the ordered content to the consumer. An activation site provides an activation certificate and a secure repository executable to consumer content-rendering devices which enables those content rendering devices to render content. The activation site 'activates+ client-reading devices in a way that binds them to a persona.

Method and system for binding enhanced software features to a persona

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Estrogen receptor modulators and uses thereof

Structural Characterization of the Human Androgen Receptor Ligand-binding Domain Complexed with EM5744, a Rationally Designed Steroidal Ligand Bearing a Bulky Chain Directed toward Helix 12

Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17β-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17β-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17β-hydroxysteroid dehydrogenase.

INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE

This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis and/or bone fracture and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein.

Prevention and treatment of androgen - deprivation induced osteoporosis

Novel methods of treating and/or inhibiting development of prostatic cancer, benign prostatic hyperplasia, prostatitis, acne, seborrhea, hirsutism or androgenic alopecia utilize inhibitors of type 3 3α-hydroxysteroid dehydrogenase alone or in combination with other active pharmaceuticals such as inhibitors of type 5 17β-hydroxysteroid dehydrogenase. Novel inhibitors and pharmaceutical products are also disclosed.

INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE

Compounds having the structure, their salts or N-oxide derivatives: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators

Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some of these compounds having tissue-specific antiandrogenic activity and tissue-specific androgenic activity can be used to treat or reduce the risk of developing diseases related to loss of androgenic stimulation. Combinations with other active pharmaceutical agents are also disclosed.

Helix 12 directed pharmaceutical products

Certain benzopyran antiestrogens are disclosed for treating estrogen sensitive diseases such as breast cancer. Prodrug forms provide ease of manufacturing, good shelf life, and bioavailibility.

Benzopyran-containing compounds and prodrug forms thereof

APERFEIcOAMENTO EM COMPOSTO OPTICAMENTE ATIVO OU SAL FARMACEUTICAMENTE ACEITaVEL DO MESMO E COMPOSIcaO CONTENDO O REFERIDO COMPOSTO Os propositos acima e outros sao providos por os compostos aqui descritos, por suas composicoes farmaceuticas e pela utilizacao dos compostos da invencao (ou das composicoes farmaceuticas contendo os mesmos) no tratamento de doencas de dependencia de esteroide sexual Por exemplo, acredita-se que câncer de mama, câncer endometrial e outras doencas de dependencia estrogenica, cujos inicio e progresso sao facilitados pela atividade do estrogenio, respondam favoravelmente ao tratamento com os compostos e composicoes da invencao

Gauthier Sylvain

Papers

INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE

17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators

Helix 12 directed pharmaceutical products

Benzopyran-containing compounds and prodrug forms thereof

aperfeiçoamento em composto opticamente ativo ou sal farmaceuticamente aceitável do mesmo e composição contendo o referido composto